Pre-morbid statin use was not significantly associated with reduced mortality following serious injury, yielding a risk ratio of 0.66 (95% CI 0.37-1.17) with high heterogeneity.
Meta-Analysis (n=105,675)
Does pre-morbid statin use reduce mortality in trauma patients?
Pre-morbid statin use was not associated with a statistically significant reduction in mortality following serious injury, though findings are heavily limited by extreme heterogeneity and observational biases.
Effect estimate: RR 0.66 (95% CI 0.37-1.17)
Secondary injury after trauma is responsible for significant morbidity and mortality. Inflammation appears to play a central role. Some evidence proposes that statins (HMG-CoA reductase inhibitors) may modulate this inflammation via their pleiotropic properties (non-cholesterol lowering effects). These include suppression of complement activation, vasodilation and inhibition of platelet function and aggregation. The purpose of this systematic review and meta-analysis was to investigate whether pre-morbid statin use is associated with differences in outcomes after trauma. MEDLINE, EMBASE, Central, Google Scholar, clinicaltrials.gov, clinicaltrialsregister.eu and the German clinical trials register were searched for articles published between 01.09.1987 and 31.12.2023 examining pre-morbid statin use on outcomes after trauma. After removal of duplicates, 623 records for abstract review were identified, of which nine were included in the systematic review and eight the meta-analysis. All studies were retrospective and most did not confirm in-hospital administration of pre-morbid statins. All had a high risk of bias. Grading of Recommendations Assessment indicated a very low certainty of results. When considering pre-morbid statin use in all types of trauma, the overall mortality risk ratio was 0.66 (95% CI 0.37–1.17) with high heterogeneity (I2 = 99%). The use of statins before traumatic brain injury (TBI) indicated a mortality risk ratio of 0.60 (95% CI 0.28–1.27, I2 = 96%). Analysis non-TBI studies yielded a risk ratio of 0.84 95% CI 0.56–1.27. In a limited meta-analysis, data failed to demonstrate an association between pre-morbid statin use following serious injury. As this may be due to a heterogeneity in data, variable study population, and a number of confounding factors, further dedicated study is warranted to clarify whether observed associations reflect pharmacologic effects.
Markle et al. (Thu,) conducted a meta-analysis in Trauma (n=105,675). Pre-morbid statins vs. No pre-morbid statin use was evaluated on Mortality (RR 0.66, 95% CI 0.37-1.17). Pre-morbid statin use was not significantly associated with reduced mortality following serious injury, yielding a risk ratio of 0.66 (95% CI 0.37-1.17) with high heterogeneity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: